Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Produ...
20 August 2015 - 10:35PM
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology
company developing therapeutic and diagnostic product candidates in
orphan indications and neurology, announced that the U.S. Patent
and Trademark Office (USPTO) issued U.S. Patent No. 9,115,208
entitled, "Dopaminergic Neuronal Survival-Promoting Factors and
Uses Thereof." The patent covers additional intellectual property
protection for MANF (mesencephalic-astrocyte-derived neurotrophic
factor) protein therapy and cell therapy. The patent covers
compositions of matter and methods of use related to the Company's
proprietary manufacturing process for synthetic MANF and its
administration.
"The issuance of this key patent covering the proprietary
compositions of matter and methods of use for MANF is very
important to our intellectual property portfolio as we work towards
the submission of a U.S. investigational new drug application for
MANF for the treatment of retinitis pigmentosa over the course of
the next 12-18 months," said Gerald E. Commissiong, President &
CEO of Amarantus. "We continue to advance our pre-clinical research
and development programs for MANF in other orphan ophthalmological
indications and in Parkinson's disease and believe this patent is
key to building a robust patent estate with the ultimate goal of
realizing MANF's full commercial potential in high value
indications."
Native MANF is currently under development for the treatment of
orphan ocular indications, including retinitis pigmentosa (RP).
Amarantus recently received both U.S. and European orphan drug
designation for MANF for the treatment of RP. In addition to RP and
Parkinson's disease, proof-of-concept preclinical models have also
demonstrated that MANF proteins have the potential to treat a wide
range of other conditions, including retinal artery occlusion,
diabetes, ischemic heart disease and other chronic disorders.
About Mesencephalic-Astrocyte-derived Neurotrophic
Factor (MANF)
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is
believed to have broad potential because it is a
naturally-occurring protein produced by the body for the purpose of
reducing and preventing apoptosis (cell death) in response to
injury or disease, via the unfolded protein response. By
manufacturing MANF and administering it to the body, Amarantus is
seeking to use a regenerative medicine approach to assist the body
with higher quantities of MANF when needed. Amarantus is the
front-runner and primary holder of intellectual property around
MANF, and is initially focusing on the development of MANF-based
protein therapeutics. MANF, a naturally-occurring protein that
reduces and prevents apoptosis (programmed cell death) in response
to injury or disease, was discovered utilizing Amarantus'
proprietary PhenoGuard™ Protein Discovery Engine.
MANF's lead indication is retinitis pigmentosa, and additional
indications including Parkinson's disease, diabetes and Wolfram's
syndrome are currently being pursued. Further applications for MANF
may include Alzheimer's disease, traumatic brain injury, myocardial
infarction, antibiotic-induced ototoxicity and certain other rare
orphan diseases currently under evaluation.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology
company developing treatments and diagnostics for diseases in the
areas of neurology and orphan diseases. AMBS' Therapeutics division
has development rights to eltoprazine, a small molecule currently
in a Phase 2b clinical program for Parkinson's disease
levodopa-induced dyskinesia with the potential to expand into adult
ADHD and Alzheimer's aggression. The Company has an exclusive
worldwide license to intellectual property rights associated to
Engineered Skin Substitute (ESS), an orphan drug designated
autologous full thickness skin replacement product in development
for the treatment of severe burns currently preparing to enter
Phase 2 clinical studies. AMBS owns the intellectual property
rights to a therapeutic protein known as
mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is
developing MANF as a treatment for orphan ophthalmic disorders,
initially in retinitis pigmentosa (RP). AMBS also owns the
discovery of neurotrophic factors (PhenoGuard™) that led to MANF's
discovery.
AMBS' Diagnostics division owns the rights to MSPrecise®, a
proprietary next-generation DNA sequencing (NGS) assay for the
identification of patients with relapsing-remitting multiple
sclerosis (RRMS), and has an exclusive worldwide license to the
Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's
disease, which was developed by Prof. Thomas Arendt, Ph.D., from
the University of Leipzig, and owns further intellectual property
for the diagnosis of Parkinson's disease (NuroPro®).
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024